On Jul. 15, 2020, Tevogen Bio announced its intention to evaluate its proprietary antigen-specific T cell technology as a potential treatment for COVID-19 patients.< In addition, Tevogen also announced developing of a bivalent COVID-19 and Influenza vaccine to assess its ability to generate cellular immunity.